A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Early initiation of pimavanserin among patients with Parkinson disease psychosis were more likely to experience complete symptom resolution.

Dr. Nir Barzilai, the director of the Institute for Aging Research at the Albert Einstein College of Medicine and board member at The American Federation for Aging Research (AFAR), predicts it will ...

After more than 54 years of marriage, John and Carol Phillips are facing their biggest struggle yet: Carol’s expensive battle with Parkinson’s disease. According to Parkinson’s Canada, the ...

There weren’t differences in the intensity of pain, familial history of headache, prodromal or early symptoms or triggers, or the use of symptomatic drugs. People with Parkinson’s disease ...

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications primarily used to treat type 2 diabetes. GLP-1s work by regulating the production of insulin and lowering your blood sugar.

Spanning nearly 100 laboratories in 45 countries, landmark research has, for the first time, shown an association between genetic brain size and neurological conditions such as Parkinson's disease ...